Market
Outcome of initial human trials for Russian mRNA cancer vaccine by end of 2025
2
Resolution / Starting Odds
Successful with no major issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trials delayed • 25%
Results published by the University of Science and Technology Sirius or the Gamaleya National Research Center
Story
Russian mRNA Cancer Vaccine, Free for Citizens, Set for 2025 Launch After Pre-Clinical Trials
Dec 26, 2024, 05:00 AM
Russian scientists have developed a personalized mRNA cancer vaccine, which has shown promising results in pre-clinical trials. The vaccine, developed by the University of Science and Technology Sirius and the Gamaleya National Research Center, is designed to be tailored to each patient's tumor, identifying unique genetic mutations known as neoantigens. These neoantigens are used to train the patient's immune system to recognize and attack cancer cells, utilizing an mRNA platform. The vaccine aims to suppress tumor development and metastasis, acknowledging that no two tumors are similar. Plans are in place to start human trials in September 2025, with the vaccine expected to be available to Russian citizens for free in 2025 at a cost of 3000 dollars per dose to the state. The development of this vaccine began in mid-2022 by the team behind Russia's Sputnik V Covid-19 vaccine.
View original story
Similar markets
Yes • 50%
No • 50%
50,001 to 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
More than 100,000 • 25%
70-79% efficacy • 25%
Above 90% efficacy • 25%
Below 70% efficacy • 25%
80-90% efficacy • 25%
WHO Recognition • 25%
EU Approval • 25%
U.S. FDA Approval • 25%
No International Recognition • 25%
WHO Approval • 25%
No Major Approval • 25%
US FDA Approval • 25%
EU Approval • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
10,000 to 50,000 • 25%
Less than 10,000 • 25%
